Grünenthal Expands Its Footprint in Latin America
Grünenthal has recently declared its determination to broaden its business operations by acquiring the commercial rights to Cialis, previously held by Eli Lilly and Company. This strategic acquisition enables Grünenthal to strengthen its presence in the Latin American markets, specifically focusing on men's health products.
Transfer of Manufacturing Operations
As part of this agreement, Grünenthal will begin transitioning the manufacturing of Cialis to its facility located in Chile. This site will ensure a robust supply for markets in Latin America, enhancing the efficiency and availability of this essential therapeutic option for patients.
Investments Driving Growth
Since 2017, Grünenthal has committed over €2 billion to various mergers and acquisitions, which has significantly bolstered its financial health and operational strength. Such investments underscore the company's commitment to enhancing its portfolio with established medications while also improving its profitability.
By acquiring Cialis, a well-known treatment for erectile dysfunction and benign prostatic hyperplasia, Grünenthal not only diversifies its offerings but also addresses an important area in men's health that requires attention. The company looks forward to consolidating its position in the Latin American pharmaceutical market.
Strategic Focus and Future Aspirations
Gabriel Baertschi, the CEO of Grünenthal, emphasized the importance of this acquisition as a vital part of the company's strategy aimed at targeted growth. He stated, "Acquiring Cialis will enhance our existing portfolio and empower us to better serve our clientele across Latin America. Our earlier acquisition of Nebido equips us to meet various health needs, and with Cialis, we are poised for further growth in this segment."
This acquisition aligns with Grünenthal’s ambition to continually bring established medicines to market, having previously secured rights to other reputable medications including Nebido and Vimovo. Furthermore, the establishment of Grünenthal Meds, a partnership with Kyowa Kirin, has allowed for the management of a diverse range of pain management brands.
About Grünenthal
Grünenthal is globally recognized as a leader in pain management and is committed to developing innovative therapies. The company operates as a fully integrated pharmaceutical entity dedicated to advancing treatments and technologies that improve quality of life for patients around the globe. Its ultimate vision is a world free of pain, upheld by its ongoing passion for innovation.
Headquartered in Aachen, Germany, Grünenthal boasts a wide-reaching presence across 28 countries in Europe, Latin America, and the United States, providing access to its offerings in roughly 100 nations. In recent years, the company has reported significant workforce growth, alongside revenues reaching approximately €1.8 billion, reflecting its successful expansion and strategic endeavors.
Frequently Asked Questions
What countries are included in Grünenthal's new acquisition of Cialis?
Grünenthal is acquiring the commercial rights to Cialis in Mexico, Brazil, and Colombia.
Why is the acquisition of Cialis significant for Grünenthal?
This acquisition allows Grünenthal to enhance its offerings in men’s health and strengthen its market position in Latin America.
Where will Cialis be manufactured after the acquisition?
Cialis will be produced at Grünenthal's manufacturing site in Chile, ensuring efficient supply for the Latin American markets.
How much has Grünenthal invested in mergers and acquisitions since 2017?
Grünenthal has invested over €2 billion in various mergers and acquisitions, enhancing its operational strength.
What is Grünenthal's mission as a pharmaceutical company?
Grünenthal aims to change lives for the better through innovative treatments, focusing on its vision of a world free of pain.
